Back

Lunai licenses Tanaist technology to validate three Parkinson’s subtypes

Verifying
  • Lunai licensed Tanaist’s cellular phenotyping technology for Parkinson’s disease programs.
  • Lunai’s Augusta analysis found three subtypes among more than 650 PPMI participants.
  • The agreement follows Lunai’s August 2026 collaboration with BrainStorm Therapeutics.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.